SuperGen ceo joins BIO board

James Manuso joins the US-based biotechnology organisation

James Manuso, chief executive of SuperGen, a US developer of novel cancer therapies, has been elected to the board of the Biotechnology Industry Organization (BIO), based in Washington, DC.

BIO’s board includes members of the governing boards for each of the organisation’s four sections: health, emerging companies, industrial and environmental and food and agriculture. Manuso has joined BIO’s health section governing board.

In addition, Manuso will serve on the BIO board Standing Committee on International Affairs.

SuperGen has been a member of BIO since 2003.

Manuso has been SuperGen chairman, president and chief executive since January 2004. He is co-founder and immediate past president and chief executive of Galenica Pharmaceuticals.

The Biotechnology Industry Organization (BIO) represents more than 1,100 biotechnology companies, academic institutions, biotechnology centres and related organisations across the US and in more than 30 other nations.

BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

You may also like

Finance

SuperGen to acquire Astex Therapeutics

Creating an international developer of cancer drugs
Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Pharmaceutical

New research suggests repurposed diabetic drug may help prostate cancer

A class of medication called SGLT2 inhibitors, traditionally used for diabetes, may help slow prostate cancer progression in men receiving hormone treatment
Drug Delivery

Indonesia looks to oral GLP-1s as it battles rising obesity

Novo Nordisk's oral GLP-1 therapy for chronic weight management could help the country deliver injectable-comparable weight loss alongside cardiovascular risk-reduction benefits for its expanding population
Pharmaceutical

Astoriom acquires Precision Stability Storage, expanding sample management capabilities

The acquisition strengthens Astoriom’s stability storage capabilities to meet increasing demand across North America and offers reliable, compliant and accessible solutions to advance scientific discovery and product development
Manufacturing

Key factors in engineering a perfect vacuum drying cycle – from agitator stroke to cake height

Pharmaceuticals demand exceptional control at every stage of production to maintain product integrity and maximise recovery. Drying is particularly critical, as it determines how much material is recovered and whether key attributes like stability, crystal form, and residual solvent content remain within specification
Subscribe now